Group-2 innate lymphoid cells (ILC2s) are a critical innate source of type-2 cytokines in 27 allergic inflammation. Although ILC2s are recognized as a critical cell population in the 28 allergic inflammation, the regulatory mechanism(s) of ILC2s are less well understood. 29
Introduction 46
Group-2 innate lymphoid cells (ILC2s) produce a large quantity of type-2 cytokines 47 including IL-5, IL-9, and IL-13 and thus are considered an innate counterpart of Th2 48 cells (1-4). ILC2s do not express a specific antigen receptor but quickly respond to 49 epithelial-derived cytokines such as IL-33 and IL-25 (also known as IL-17E) (4). This 50 epithelial cytokine-mediated ILC2 activation is sufficient to induce allergic pulmonary 51 inflammation evoked by the instillation of papain (5, 6) , house dust mite (7, 8), or 52 Alternaria alternata (9, 10) in mice. ILC2s are also essential for early host protection 53 against helminth infections including Nippostrongylus brasiliensis (N. brasiliensis) (3, 54 11 ). In addition to acute type-2 inflammation, ILC2s contribute to chronic phase of 55 type-2 inflammation by activating Th2 cells (12, 13) and by acquiring a memory-like 56 phenotype (14) . Indeed, ILC2s are implicated in human chronic type-2 disorders 57 including chronic rhinosinusitis (15, 16) and allergic asthma (17) (18) (19) . Thus, a deeper 58 understanding of the regulatory mechanisms of ILC2 activation is essential to develop 59 therapeutic measures for type-2 immunity associated disorders. 60 10 The co-stimulatory molecule ICOS is essential for ILC2 activation (40) (41) (42) . Compared 163 with IL-2 alone, IL-2/33 stimulation upregulated all three molecules in WT ILC2; 164 however, this upregulation was significantly attenuated in Regnase-1 AA/AA ILC2 165 (Figure 2, C and D) . ICOS and ST2 levels were slightly but significantly 166 down-regulated in IL-2/25-stimulated Regnase-1 AA/AA ILC2. IL-2Ra was not 167 upregulated by IL-2/25 stimulation even in WT cells. Because forced expression of 168
Regnase-1 induces cellular apoptosis (43, 44) , we examined ILC2 cell death after 169 cytokine stimulation. Both IL-2/33 and IL-2/25 induced higher cell death 170 (7-aminoactinomycin-D (7-AAD) + and/or annexin-V + cells) in Regnase-1 AA/AA ILC2s 171 compared with WT cells (Figure 2, E and F) . Intracellular IL-5 and IL-13 staining 172 showed decreased cytokine staining in IL-2/33-, but not IL-2/25-, stimulated 173
Regnase-1 AA/AA ILC2s (Figure 2, G and H) . IL-9 production promotes ILC2 survival 174 and cytokine production in an autocrine manner (45, 46) . However, exogenous IL-9 did 175 not rescue the reduced IL-5/IL-13 production from Regnase-1 AA/AA ILC2s 176 (Supplemental Figure 2C and D) . 177
To assess whether decreased cytokine production and surface molecule 178 expression in Regnase-1 AA/AA ILC2 occurred at the mRNA level, Regnase-1 WT/WT and 179
Regnase-1 AA/AA BM ILC2s were stimulated with IL-2/33 or IL-2/25 for 1 or 2 days. The 180 expression of Il5, Il9, Il13, Icos, and Il2ra were upregulated by IL-2/33 stimulation, and 181
Regnase-1 AA/AA ILC2s showed significantly decreased expression of these mRNAs 182 other than Icos mRNA (Figure 3A) . Although Il1rl1 (which encodes ST2) was not 183 upregulated by IL-2/33 stimulation in WT cells, IL-2/33 stimulation over time and were accumulated in the lungs of IL-33 administered Regnase-1 WT/WT , but not 229
Regnase-1 AA/AA , mice (Figure 5E and Supplemental Figure 5D ). Numbers of 230 ST2 + ILC2s (CD45 + Lin -ST2 + CD90.2 + Sca-1 + cells) (Figure 5E and Supplemental 231 Figure 5E and F) and percentages of IL-5/IL-13 producing ILC2s (within 232 CD45 + Lin -ST2 + cells) (Figure 5F and Supplemental Figure 5G ) in the lungs were 233 markedly lower in IL-33 administered Regnase-1 AA/AA mice compared with WT mice. 234
Concomitantly, IL-5 and IL-13 concentrations in BAL fluids (BALFs) were 235 significantly lower in IL-33 administered Regnase-1 AA/AA mice (Supplementary 236 Figure 6E ). IL-13 induces lung mucin production (49). We found that Periodic 237 acid-Schiff (PAS)-positive cells (Figure 5C ) and the expression of Muc5ac, which 238 encodes a mucin protein, (Figure 5G) were decreased in the lungs of Regnase-1 AA/AA 239 mice administered IL-33. Similar to IL-33, Regnase-1 AA/AA mice showed decreased the expression of Il33 in WT mice probably through the induction of inflammation, it 254 was abrogated in Regnase-1 AA/AA mice (Supplementary Figure 7G) . 255
To examine a more physiologically relevant model, we used papain, an 256 allergen that induces ILC2-mediated type-2 pulmonary inflammation (5, 6) . 257
Regnase-1 WT/WT and Regnase-1 AA/AA mice were i.n. administered papain for 4 258 consecutive days, and analyzed 24 h after the final challenge ( Figure 7A ). Papain 259 induced lung inflammatory cell infiltration even in Regnase-1 AA/AA mice (Figure 7B-D) . including monocytes, neutrophils, macrophages, and lymphocytes were accumulated in 266 the lungs and BALs of Regnase-1 WT/WT and Regnase-1 AA/AA mice (Supplemental 267 Figure 9G and 10E) . This phenotype is similar to that observed for ST2-deficient mice 268 Figure 7G) were decreased in the lungs of 273 papain administered Regnase-1 AA/AA mice. Overall, Regnase-1 AA/AA mice showed 274 milder papain-induced lung pathology scores compared with WT mice (Figure 7D) . 275
Il33 was upregulated by a single papain administration in WT mice as previously 276 reported (52), and it was not abrogated in Regnase-1 AA/AA mice (Supplementary 277 Figure 9H ). Therefore, the defective response to IL-33 may explain the phenotype 278 observed in papain administered Regnase-1 AA/AA mice. 279
280
Regnase-1 AA/AA mice are susceptible to helminth infection. 281
Finally, we assessed the role of Regnase-1 degradation in N. brasiliensis infection. 282
Regnase-1 WT/WT and Regnase-1 AA/AA mice were infected with L3 larvae of N. 283 brasiliensis (Figure 8A ). Intestinal worm burden was higher in Regnase-1 AA/AA mice 284 than WT mice on day 7, but not on day 5, post infection ( Figure 8B) indicating delayed 285 worm expulsion in Regnase-1 AA/AA mice. Concomitantly, lung infiltration of CD45 + 286 hematopoietic cells and eosinophils was significantly lower in Regnase-1 AA/AA mice 287 ( Figure 8C ). Although the difference of ST2 + ILC2s numbers between Regnase-1 WT/WT 288 and Regnase-1 AA/AA mice was relatively small and only statistically significant on day 7 289 ( Figure 8C) , the percentage of IL-5/IL-13 producing ILC2s was lower in 290
Regnase-1 AA/AA mice on days 5 and 7 ( Figure 8D) . 291
Taken together, these observations demonstrate that Regnase-1 degradation 292 plays a critical role in activating ILC2 in vivo and in acute type-2 pulmonary 293 inflammation. 294
Discussion 295
Regnase-1 has been described as a negative regulator of Th1/Th17 inflammatory 296 responses by controlling mRNA stability (20, 21, 32, 33) . In this study, we showed that 297
Regnase-1 also contributes to type-2 immune responses by regulating IL-33-and 298 IL-25-mediated ILC2 activation. 299
Although Regnase-1 was identified as an LPS-inducible gene (20), 300 macrophages and fibroblasts constitutively expressed Regnase-1 protein (22) . Once 301 cells are activated through TLR/IL-1R, Regnase-1 undergoes degradation leading to a 302 temporal decrease of Regnase-1 followed by its de novo synthesis. The canonical 303 IKK-target motif (DSGxxS) in Regnase-1 (S435/S439) is essential for TLR/IL-1R 304
induced Regnase-1 degradation. This study demonstrated that the IKK-target motif in 305
Regnase-1 was also essential for Regnase-1 degradation in IL-33-stimulated ILC2s, as 306
Regnase-1 accumulated in IL-2/33-stimulated Regnase-1 AA/AA ILC2s. In addition to 307 IKKs, IRAK1 phosphorylates Regnase-1 at S494/S513, to form a slowly migrating 308
Regnase-1 by immunoblotting, promoting the subcellular translocation from the 309 endoplasmic reticulum to the cytoplasm, in which the IKK complex engages to 310 phosphorylated Regnase-1 to facilitate its degradation (22, 23) . Upon stimulation of 311 ILC2s with IL-2/33, a slowly migrating Regnase-1 signal was observed within 15 min 312 by immunoblotting. Therefore, because IL-33R shares signaling molecules with 313 TLR/IL-1R (25), in IL-2/33-stimulated ILC2s, Regnase-1 can undergo 314 IRAK1-mediated quick phosphorylation followed by IKK-mediated degradation as in 315 TLR/IL-1R-stimulated cells. 316
Regnase-1 is also involved in IL-17-induced immune responses (32, 33, 53) . 317
Regnase-1 S435/S439 controls Regnase-1 degradation in IL-17-stimulated fibroblasts, 318 and TBK1/IKKi are substitutes for the role of IRAK1 (23). Here, we showed that 319
Regnase-1 accumulated in IL-2/25-stimulated Regnase-1 AA/AA ILC2s. Although a 320 slowly migrating Regnase-1 was barely detectable in IL-2/25-stimulated WT ILC2s, it 321 accumulated in Regnase-1 AA/AA ILC2s. Thus, TBK1/IKKi-mediated Regnase-1 322 phosphorylation exists downstream of IL-25, but phosphorylated Regnase-1 might be 323 quickly degraded in WT cells. Therefore, because IL-17 and IL-25 belong to the same 324 cytokine family and share Act1 as an adaptor molecule which interacts with Regnase-1 325 to induce TBK1/IKKi-mediated phosphorylation (23, 29), Regnase-1 may be controlled 326 downstream of IL-25 in ILC2s by a similar mechanism in IL-17-stimulated cells. 327 IL-33 induced greater Regnase-1 accumulation in Regnase-1 AA/AA ILC2s 328 compared with IL-25. IL-33 was reported to have a greater ILC2-activating capacity 329 compared with IL-25 both in vitro and in vivo (7, 54) . This stronger ILC2 activation by 330 IL-33 may explain the higher accumulation of Regnase-1 in IL-2/33-stimulated 331
Regnase-1 AA/AA ILC2s. Because of the higher Regnase-1 accumulation, IL-2/33-332 stimulated Regnase-1 AA/AA ILC2s might show a greater decrease in cell proliferation 333 and cytokine production, and increase in cell death compared with IL-2/25-stimulated 334
cells. Forced Regnase-1 expression induced cellular apoptosis (44), indicating 335
Regnase-1 accumulation in IL-2/33-or IL-2/25-stimulated Regnase-1 AA/AA ILC2s 336 might increase cell death. Intracellular IL-5/IL-13 staining was comparable between 337 IL-2/25-stimulated Regnase-1 WT/WT and Regnase-1 AA/AA ILC2s and IL-25-inducible mRNA levels were not decreased in Regnase-1 AA/AA ILC2s. Thus, increased ILC2 cell 339 death might decrease cytokine production from IL-2/25-stimulated Regnase-1 AA/AA 340
ILC2s. In addition to increased cell death, IL-2/33 stimulation decreased cytokine 341 production on a per-cell-basis and destabilized Il2ra and Il1rl1 mRNAs in 342
Regnase-1 AA/AA ILC2s. Although the expression of Il5, Il9, and Il13 mRNAs was 343 decreased in IL-2/33-stimulated Regnase-1 AA/AA ILC2s, their stabilities were 344 comparable between Regnase-1 WT/WT and Regnase-1 AA/AA ILC2s. Therefore, Il5, Il9, 345
and Il13 mRNA might not be direct targets for Regnase-1 in ILC2s, and their reduced 346 expression in IL-2/33-stimulated Regnase-1 AA/AA ILC2s might be a secondary effect of 347 decreased signaling from IL-2R and IL-33R. Taken together, the decreased expression 348 of IL-2R and IL-33R, and increased cell death might explain decreased cytokine 349 production from IL-2/33-stimulated Regnase-1 AA/AA ILC2s. papain-induced lung inflammation and reduced early resistance to N. brasiliensis infection in Regnase-1 AA/AA mice. In addition to ILC2s, defects in other innate and 361 adaptive cell populations might be involved in the overall phenotype of Regnase-1 AA/AA 362 mice observed in the current study, as Regnase-1 also controls Th2 activation 363 downstream of T cell receptor signaling (34) . 364
Il2ra and Il1rl1 mRNAs were destabilized in IL-33-stimulated, but not in 365 IL-25-stimulated, Regnase-1 AA/AA ILC2s. This might be explained by the amount of 366
Regnase-1 accumulated in ILC2s. Il2ra and Il1rl1 half-lives were comparable between 367
Regnase-1 WT/WT and Regnase-1 AA/AA ILC2s at 4 h after IL-2/33 stimulation, but were 368 significantly decreased in Regnase-1 AA/AA ILC2s at 24 and 48 h after IL-2/33 369 stimulation. Therefore, relatively high-level Regnase-1 accumulation might be required 370 to destabilize mRNAs, and Regnase-1 accumulated in IL-2/25-stimulated 371
Regnase-1 AA/AA ILC2s might not be sufficient to destabilize the mRNAs. Although the 372 defect in cytokine production in IL-25-stimulated Regnase-1 AA/AA ILC2 was milder 373 than that observed in IL-33-stimulated cells, the in vivo response to IL-25 374 administration was almost completely abrogated in Regnase-1 AA/AA mice. Because 375 IL-25 administration induced the upregulation of Il33 in Regnase-1 WT/WT , but not in 376
Regnase-1 AA/AA , mice, the phenotype observed in IL-25 administered Regnase-1 AA/AA 377 mice should be the sum of the reduced response of the mice to both IL-25 and Further study is required to clarify the exact differential role of Regnase-1 and its 379 degradation downstream of IL-33 and IL-25. 380
The stability of Regnase-1 targets found in CD4 + T cells, such as Icos and 381
Gata3 (21, 34), were not different between Regnase-1 WT/WT and Regnase-1 AA/AA ILC2s.
Regnase-1 might control mRNAs in a cell type-specific manner by interacting with 383 specific partner(s) in the cell population. Alternatively, although Icos and Gata3 384 mRNAs were stabilized in Regnase-1-deficient CD4 + T cells, excessive Regnase-1 385 expression in Regnase-1 AA/AA cells might not affect the stability. 386
Because Regnase-1 AA/AA ILC2s expressed unusually high-levels of Regnase-1 387 after IL-33-or IL-25-stimulation, the role of Regnase-1 discovered in this study might 388 be specific because of its "overexpression". Even so, our study demonstrated the 389 potential therapeutic use of Regnase-1 degradation inhibitor(s) for treating allergic 390 disorders. For instance, IKKb inhibitor(s) are candidates for anti-asthmatic agents by 391
inhibiting 58) . In addition to suppressing NF-kB, our results suggest that 392
IKKb inhibitor(s) decrease ILC2 activity by increasing cellular Regnase-1 levels. 393
Because ILC2s and their activation are implicated in the pathogenesis of severe and 394 treatment-resistant asthma (18, 19, 59) , Regnase-1 degradation inhibitor(s) might be 395 beneficial for treating severe/refractory asthma. 396
In summary, we showed that Regnase-1 degradation was essential for 397 ILC2-mediated type-2 responses both in vitro and in vivo. Although we only studied 398 acute type-2 inflammation models, ILC2s might be also involved in chronic and 399 treatment-resistant allergic disorders (15) (16) (17) (18) (19) . Therefore, controlling Regnase-1 activity 400 is a potential therapeutic target for severe and/or uncontrolled allergic disorders. 401
Methods 402
Mice 403 C57BL/6 WT mice were purchased from Oriental Yeast (Tokyo, Japan). 404 C57BL/6-background Regnase-1 AA/AA mice were generated as described (23). Mice 405
were maintained under specific pathogen-free conditions at the animal facilities of 406
Hyogo College of Medicine. 407 408
Reagents 409
Rabbit anti-mouse-Regnase-1 monoclonal antibody (mAb) (23) and recombinant human 410 IL-33 (60) were prepared as described. Recombinant human IL-2 and mouse IL-9 were 411 purchased from PeproTech (Hamburg, Germany). Recombinant and mouse IL-25 and 412 mouse TSLP was purchased from R&D systems (Minneapolis, MN). Actinomycin-D, 413
anti-DNP mouse IgE (SPE-7), ionomycin (A23187), papain from papaya latex, and 414 phorbol 12-myristate 13-acetate (PMA) were from Sigma-Aldrich Japan (Tokyo, Japan). 415
TPCA-1 was from abcam (Cambridge, UK). Anti-mouse-IgE mAb (23G3) was 416 purchased from Southern Biotechnology Associates, Inc (Birmingham, AL, USA). 417
Anti-mouse-ST2 mAb (DJ8) was purchased from MD Bioproducts (St Paul, MN, USA). 418
Anti-mouse-ERK2 mAb (C-14) was purchased from Santa Cruz (Dallas, TX, USA). 419 ECL anti-rabbit IgG HRP-Linked and ECL Prime Western Blottin Detection Reagent 420 were purchased from GE healthcare (Little Chalfont, UK). Biotin-anti-rabbit-IgG was 421 purchased from Vector Laboratories (Burlingame, CA, USA). Annexin-V and 7-AAD 422
were purchased from BD Bioscience (San Jose, CA, USA).
Alexa-Fluor-488-streptabidin was purchased from Invitrogen (Carlsbad, CA, USA). 424
Collagenase and recombinant bovine DNase-I were purchased from Wako Pure 425 Chemicals (Osaka, Japan). mAbs specific for mouse B220 (RA3-6B2), CD3ε 426 (145-2C11), CD4 (RM4-5), CD8 (53-6.7), CD11b (M1/70), CD11c (N418), CD16/32 427 was maintained in male SD rats as previously described (61). 441 442
Preparation of ILC2s and in vitro culture 443
Lineage-negative cells were enriched from BM cells using a Lineage Cell Depletion Kit 444
and AutoMACS Separator (Miltenyi Biotech, Gladbach, Germany). Then, cells were Fc-blocked with anti-CD16/32, incubated with biotin-anti-CD25-antibody and 446 anti-DNP-IgE, then stained using FITC-anti-B220, -CD3, -CD4, -CD8, -CD11b, 447 -CD11c, -CD49b, and -IgE antibodies (lineage markers) as well as PE-anti-CD90.2, 448
PerCP-Cy5.5-streptavidin, APC-anti-CD45, and Pacific Blue-anti-Sca-1. 449 CD45 + Lin -CD90.2 + CD25 + Sca-1 + cells were sorted as BM ILC2s using FACS Aria III 450 (BD Biosciences) (Supplementary Figure 1A) . In some experiments, ILC2s were 451 expanded for 10 days in complete medium containing IL-2 (3 ng/mL), IL-33 (50 452 ng/mL), and IL-25 (50 ng/mL). Then, cells were rested in medium only containing IL-2 453
(3 ng/mL) for 2-3 days before used for experiments. ILC2s were cultured in 96-well 454 palates at 1 × 10 3 cells/200 µL/well in complete medium containing the combinations of 455 IL-2 (3 ng/mL), TSLP (10 ng/mL), IL-9 (50 ng/mL), IL-33 (100 ng/mL) or IL-25 (100 456 ng/mL) for varying periods. In some experiments, ILC2s were stimulated with PMA (30 457 ng/mL) and ionomycin (500 µg/mL). For cytokine production, cell proliferation, or 458 surface molecule expression, cells were cultured for 3 days. Then, the supernatant was 459 harvested and analyzed by ELISA, and cells were subjected to FACS analysis. For 460 intracellular cytokine staining, Golgi-Stop was added for the last 4 h of culture and cells 461 were subjected to FACS analysis. To analyze mRNA half-life, ILC2s were stimulated 462 with IL-2 (3 ng/mL) and IL-33 (100 ng/mL) for 4, 24, or 48 h. Then, actinomycin D (2 463 µg/mL) was added to culture medium to stop transcription. Cells were further cultured 464 for 0, 1, 2, and 4 h and were collected for quantitative PCR analysis. 465
Mice were perfused via the right ventricle with 10 ml of PBS. Lung left lobes were 468 dissected from mice and were immediately fixed in 4% paraformaldehyde for 24 h at 469 4°C. Samples were embedded in paraffin, and then 4-μm coronal sections were cut with 470 a microtome TU-213 (Yamato Kohki Industrial, Asagiri, Japan) and stained with H&E 471 or PAS. Samples were evaluated under an AX80/DP72 microscope (Olympus Life 472
Science, Tokyo, Japan). The lung pathology scores were determined by a blinded 473 investigator in terms of bronchial and interstitial cellular infiltration, and mucus 474 production (all 0 to 5 points, thus the maximum potential score is 15). 475 476
Preparation of lung and BAL cells 477
To prepare lung cells, lung left lobes were dissected from mice and infused with 478 complete medium (RPMI 1640 medium supplemented with 10% fetal bovine serum, 479 2-ME (50 µM), L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 480 µg/mL)) containing collagenase (150 U/ml) and DNase I (10 µg/mL). Then, the 481 samples were minced and digested for 50 min at 37°C. Cell suspensions were filtered 482 using a cell strainer and red blood cells were lysed. For FACS analysis, cells were 483 suspended in ice-cold staining buffer (1% BSA in PBS). For intracellular cytokine 484 staining, lung cells were cultured in complete medium containing PMA (30 ng/mL) and 485 ionomycin (500 µg/mL) in the presence of Golgi-Stop (BD Biosciences) for 4 h. BAL 486 was performed with three aliquots of 1 mL of PBS per mouse. After centrifugation, 487
BALFs were collected and kept at −80°C for ELISA, and cells were suspended in 488 ice-cold staining buffer for FACS analysis. 25 
490

FACS analysis 491
Cells prepared from in vitro culture, lungs, or BALs were washed in ice-cold staining 492 buffer, Fc-blocked with anti-CD16/32 antibody, then incubated with each antibody 493
(1/100) for 15 min and washed twice with staining buffer. Intracellular cytokine and 494
Regnase-1 staining were performed using BD Cytofix/Cytoperm™ Plus 495
Fixation/permeabilization Kit (BD Biosciences). For intracellular Regnase-1 staining, 496 anti-mouse Regnase-1 mAb and IgG from normal rabbit sera (as a control) (19 µg/ml) 497
were used as primary antibodies. Biotin-conjugated anti-rabbit-IgG mAb (1/500) was 498 used as a secondary antibody, and Alexa-Fluor-488-streptavidin (1/500) was used as a 499 tertiary reagent. Data were acquired using a FACS Canto II flow cytometer (BD 500 Biosciences) and analyzed using FlowJo software (version 7.6.1, Tree Star Inc., 501
Ashland, OR, USA). To investigate lung inflammatory cells, Lung total hematopoietic 502 cells were defined as CD45 + singlet cells (Supplementary Figure 5A) . From the 503 CD45 + population, eosinophils (Autofluorescence -CD11b + Siglec-F + ), 504 monocytes/neutrophils (Autofluorescence -CD11b + CD11c int Siglec-F -), macrophages 505 (Autofluorescence + CD11c high Siglec-F high ), lymphocytes 506 (Autofluorescence -CD11b -FSC low SSC low ), and ILC2s (Lin -ST2 + CD90.2 + Sca-1 + ) were 507 defined (Supplementary Figure 9A-E) . In IL-25 administered mice, ILC2s were 508 divided into ST2 + (Lin -CD90.2 + ST2 + ) and ST2 -KLRG-1 + (Lin -CD90.2 + ST2 -KLRG-1 + ) 509
ILC2s (Supplementary Figure 7D) . BAL total hematopoietic cells were defined as 510 CD45 + singlet cells. From the CD45 + population, eosinophils 511 (CD11b + CD11c -Siglec-F + ), neutrophils (CD11b + CD11c -Gr-1 + Siglec-F -), macrophages 512 (CD11c high Siglec-F high ), and lymphocytes (CD11b -CD11c -FSC low SSC low ) were defined 513 ( Supplementary Figure 10B and C) . the Thermal cycler dice RT-PCR system (Takara Bio Inc., Otsu, Japan), with an initial 527 denature at 95°C for 30 s, followed by 40-45 cycles of denaturing at 95°C for 5 s and 528 annealing and extension at 60°C for 30 s. The TaqMan probes used in this study were 529 Rabbit anti-mouse Regnase-1 mAb (1.9 µg/ml) and rabbit anti-mouse ERK2 mAb 543
(1/1000) were used as primary antibodies, and ECL anti-rabbit IgG HRP-linked 544
(1/4000) was used as the detection antibody. The quantification of the bands were 545 performed using ImageQuant TL(ver8.1; GE Healthcare). The Regnase-1 levels were 546
shown as relative to ERK2 levels. 547 548
Statistical analysis 549
Two-tailed Student's t-test (to compare two groups), one-way ANOVA followed by 550
Tukey's test (to compare more than two groups), and two-way ANOVA followed by 551
Bonferroni's test (to analyze time-course experiments) were performed using Prism 6 552 (version 6.0h, GraphPad Software, La Jolla, CA, USA). P values less than 0.05 were 553 considered statistically significant. 554 28 555
Study approval 556
All animal experiments were performed with the approval of, and in accordance with, 557 the guidelines of the Institutional Animal Care Committee of Hyogo College of 558
Medicine . producing cells within CD45 + Lin -ST2 + ILC2s were quantified by intracellular cytokine staining and FACS. Pooled data from two independent experiments are shown (mean ± SEM). n=7 (day 0 WT and AA), n=9 (day 5 WT), n=8 (day 5 AA), n=10 (day 7 WT), and n=9 (day 7 AA). Significance was determined by two-way ANOVA followed by Bonferroni's test ; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. n.s. not significant.
